The Potential of Tempeh as a Chemopreventive and Chemotherapeutic Agent Targeting Breast Cancer Cells
DOI:
https://doi.org/10.3923/pjn.2017.743.749Keywords:
Anti-apoptotic, anti-proliferative, breast cancer, chemopreventive, chemotherapeutic, soybean, tempehAbstract
Background and Objective: The prevalence and incidence of breast cancer are much lower in Asian women than in Western women. However, data from various hospitals in Indonesia indicate that the incidence of breast cancer in the country has been rising by 2-8% over the last 10 years. Epidemiological studies have found that soy intake correlates to the low risk of breast cancer among Asian women. This study was conducted to prove the efficacy of tempeh consumption as a chemotherapy agent against breast cancer in DMBA-induced model animals. Materials and Methods: This study was a pre-clinical trial using a true experimental posttest-only control group design. The subjects were 25 white sprague-dawley rats that were induced with 7,12-Dimethylbenz[a]anthracene (DMBA). The observed parameters were AgNORs, BCl-2, Cas-3, p53 and VEGF. The test subjects were divided into a control group and 4 treatment groups that were given feed with modified tempeh starch contents of 1% (T1), 10% (T2), 50% (T3) and 75% (T4). Results: A tempeh diet had a significant effect on anti-proliferation and apoptosis markers in breast cancer cells (p<0.05). Conclusion: Of the four doses used in the trial, 50% tempeh flour was shown to be the most effective.
References
Hertz, R., P. Robin and S.W. Lowrenthal, 2008. The burden of cancer in Asia. Pfizer Facts. 2008. The burden of cancer in Asia. Pfizer Facts.
Youlden, D.R., S.M. Cramb, C.H. Yip and P.D. Baade, 2014. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol. Med., 11: 101-115.
Hakkak, R., S. Korourian, S.R. Shelnutt, S. Lensing, M.J. Ronis and T.M. Badger, 2000. Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats. Cancer Epidemiol. Biomark. Prev., 9: 113-117.
Messina, M. and L. Hilakivi-Clarke, 2009. Early intake appears to be the key to the proposed protective effects of soy intake against breast cancer. Nutr. Cancer, 61: 792-798.
Lamartiniere, C.A., M.S. Cotroneo, W.A. Fritz, J. Wang, R. Mentor-Marcel and A. Elgavish, 2002. Genistein chemoprevention: Timing and mechanisms of action in murine mammary and prostate. J. Nutr., 132: 552S-558S.
Zaheer, K. and M.H. Akhtar, 2017. An updated review of dietary isoflavones: Nutrition, processing, bioavailability and impacts on human health. Crit. Rev. Food Sci. Nutr., 57: 1280-1293.
Villares, A., M.A. Rostagno, A. Garcia-Lafuente, E. Guillamon and J.A. Martinez, 2011. Content and profile of isoflavones in soy-based foods as a function of the production process. Food Bioprocess Technol., 4: 27-38.
Nout, M.J.R. and J.L. Kiers, 2005. Tempe fermentation, innovation and functionality: Update into the third millenium. J. Applied Microbiol., 98: 789-805.
Pisani, P., B. Freddie and D.M. Parkin, 2002. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer, 97: 72-81.
Shu, X.O., F. Jin, Q. Dai, W. Wen and J.D. Potter et al., 2001. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol. Prevent. Biomarkers, 10: 483-488.
Thanos, J., M. Cotterchio, B.A. Boucher, N. Kreiger and L.U. Thompson, 2006. Adolescent dietary phytoestrogen intake and breast cancer risk (Canada). Cancer Causes Control, 17: 1253-1261.
Reeves, P.G., 1997. Components of the AIN-93 diets as improvements in the AIN-76A diet. J. Nutr., 127: 838S-841S.
Philip, G.R, H.N. Forrest and C.F. George Jr., 1993. AIN-93 purified diets for laboratory rodents: Final report of the American Institute of Nutrition ad hoc Writing Committee on the Reformulation of the AIN-76A Rodent Diet. J. Nutr., 123: 1939-1951.
Bintari, S.H., 2013. Pasteurization for hygienic tempe: Study case of Krobokan Tempe yesterday and today. GSTF Int. J. BioSci., 2: 39-44.
Trock, B.J., L. Hilakiri-Clarke and R. Clarke, 2006. Meta-analysis of soy intake and breast cancer risk. J. Nat. Cancer Inst., 98: 459-471.
He, F.J. and J.Q. Chen, 2013. Consumption of soybean, soy foods, soy isoflavones and breast cancer incidence: Differences between Chinese women and women in Western countries and possible mechanisms. Food Sci. Hum. Wellness, 2: 146-161.
Tjindarbumi, D. and R. Mangunkusumo, 2002. Cancer in Indonesia, present and future. Jap. J. Clin. Oncol., 32: S17-S21.
Moore, M.A., A.A. Manan, K.Y. Chow, S.F. Cornain and C.R. Devi et al., 2010. Cancer epidemiology and control in peninsular and island South-East Asia-past, present and future. Asian Pac. J. Cancer Prev., 11: 81-98.
Hussain, M., M. Banerjee, F.H. Sarkar, Z. Djuric and M.N. Pollak et al., 2003. Soy isoflavones in the treatment of prostate cancer. Nutr. Cancer, 47: 111-117.
Shu, X.O., Y. Zheng, H. Cai, K. Gu, Z. Chen, W. Zheng and W. Lu, 2009. Soy food intake and breast cancer survival. JAMA, 302: 2437-2443.
Uifalean, A., S. Schneider, C. Ionescu, M. Lalk and C.A. Iuga, 2015. Soy isoflavones and breast cancer cell lines: Molecular mechanisms and future perspectives. Molecules, Vol. 21.
Sarkar, F.S. and Y. Li, 2003. Soy isoflavones and cancer prevention. Cancer Invest., 21: 744-757.
Nishida, N., H. Yano, T. Nishida, T. Kamura and M. Kojiro, 2006. Angiogenesis in cancer. Vascular Health Risk Manage., 2: 213-219.
Varinska, L., P. Gal, G. Mojzisova, L. Mirossay and J. Mojzis, 2015. Soy and breast cancer: Focus on angiogenesis. Int. J. Mol. Sci., 16: 11728-11749.
Kinoshita, J., K. Kitamura, A. Kabashima, H. Saeki, S. Tanaka and K. Sugimachi, 2001. Clinical significance of Vascular Endothelial Growth Factor-C (VEGF-C) in breast cancer. Breast Cancer Res. Treat., 66: 159-164.
Skobe, M., T. Hawighorst, D.G. Jackson, R. Prevo and L. Janes et al., 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med., 7: 192-198.
Hockenbery, D.M., Z.N. Oltvai, X.M. Yin, C.L. Milliman and S.J. Korsmeyer, 1993. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75: 241-251.
Hague, A., M. Moorghen, D. Hicks, M. Chapman and C. Paraskeva, 1994. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene, 9: 3367-3370.
Itoi, T., K. Yamana, V. Bilim, K. Takahashi and F. Tomita, 2004. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br. J. Cancer, 90: 200-205.
Krajewski, S., A.D. Thor, S.M. Edgerton, D.H. Moore, M. Krajewska and J.C. Reed, 1997. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin. Cancer Res., 3: 199-208.
Worsley, S.D., B.A. Jennings, K.H. Khalil, M. Mole and A.C. Girling, 1996. Cyclin D1 amplification and expression in human breast carcinoma: Correlation with histological prognostic markers and oestrogen receptor expression. Clin. Mol. Pathol., 49: M46-M50.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
